InferVision, a Philadelphia, Pennsylvania-based medical artificial intelligence (AI) provider specializing in the clinical application of AI and deep learning technologies, completed its Series D2 financing led by Goldman Sachs Asset Management.
The company has raised around US$140m in total from Series D1 and D2 financing.
The proceeds will be used for R&D, distribution channels expansion and business development.
Led by CK, Founder and Chairman, InferVision uses AI and deep learning technologies to develop multiple platforms, including an AI applications management platform, an AI data-mining research platform, and several AI clinical application platforms, as well as medical A.I. systems for quality control, health management, and scientific research. The company provides advanced, intelligent, and systematic services to payors, providers, and patients.
Since its establishment in 2016, InferVision has received investments over US$210m from Sequoia Capital, Qiming Venture Partners, CDH Investments, CCB Trust and Springhill Fund.
FinSMEs
14/08/2021